Document is current
Any future updates will be listed below
-
Authors
Mizuno, Shohei
Kawamura, Koji
Hanamura, Ichiro
Sunami, Kazutaka https://orcid.org/0000-0002-8229-7439
Mori, Takehiko https://orcid.org/0000-0002-8176-4760
Nakamura, Fumihiko
Iida, Shinsuke
Nakazawa, Hideyuki
Makita, Masanori
Kako, Shinichi
Sawa, Masashi
Ueda, Yasunori
Takahashi, Hiroyuki
Kanda, Yoshinobu
Ichinohe, Tatsuo
Atsuta, Yoshiko
Takamatsu, Hiroyuki
Takami, Akiyoshi
- License Information
-
More Information
Article History
Received: 21 October 2018
Revised: 31 January 2019
Accepted: 4 February 2019
First Online: 19 February 2019
Compliance with ethical standards
:
: SM received honoraria from Takeda Pharmaceutical Co., Ltd. and received research funding from Kyowa Hakko Kirin Co., Ltd, Chugai Pharmaceutical Co., Ltd, and Bristol-Myers Squibb Corporation. IH received lecture fee from Celgene Corporation, Bristol-Myers Squibb Corporation, Janssen Corporation, Takeda Pharmaceutical Co., Ltd, and Eisai Co., Ltd, and received research funding from Fujimoto Pharmaceutical Corporation, Kyowa Hakko Kirin Co., Ltd, Chugai Pharmaceutical Co., Ltd, and Bristol-Myers Squibb. KS received honoraria from Ono Pharmaceutical Co., Ltd, Bristol-Myers Squibb Corporation, and Celgene Corporation, and received research funding from Ono Pharmaceutical Co., Ltd, Bristol-Myers Squibb Corporation, Celgene Corporation, Janssen Corporation, Takeda Pharmaceutical Co., Ltd, Sanofi Corporation, Abbvie Corporation, GlaxoSmithKline plc, MSD Corporation, and Daiichi Sankyo Co., Ltd. HT received honoraria from Celgene Corporation and Janssen Corporation, and received research funding from Ono Pharmaceutical Co., Ltd, Bristol-Myers Squibb, and Celgene Corporation. AT received research funding from Kyowa Hakko Kirin Co., Ltd, Chugai Pharmaceutical Co., Ltd, and Bristol-Myers Squibb Corporation.
